Section Arrow
LRMR.NASDAQ
- Larimar Therapeutics
Quotes are at least 15-min delayed:2026/04/10 17:36 EDT
After Hours
Last
 4.81
-0.04 (-0.82%)
Bid
4.71
Ask
5.4
High 4.85 
Low 4.81 
Volume 3.63K 
Regular Hours (Closed)
Last
 4.85
-0.24 (-4.72%)
Day High 
5.14 
Prev. Close
5.09 
1-M High
Volume 
1.90M 
Bid
4.71
Ask
5.4
Day Low
4.775 
Open
5.11 
1-M Low
4.2 
Market Cap 
528.76M 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 4.8 
20-SMA 4.67 
50-SMA 4.32 
52-W High 6.42 
52-W Low 1.73 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-2.27/-1.52
Enterprise Value
531.73M
Balance Sheet
Book Value Per Share
0.75
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
CUECue Biopharma0.5019+0.209+71.36%-- 
After Hours 0.4411 -0.0608 -12.11%
QNCXQuince Therapeutics0.1363+0.0126+10.19%-- 
After Hours 0.1211 -0.0152 -11.15%
VRAXVirax Biolabs Group Limited0.1041-0.0308-22.83%-- 
After Hours 0.1721 +0.068 +65.32%
ZNTLZentalis Pharmaceuticals6.61+2.19+49.55%-- 
After Hours 6.6151 +0.0051 +0.08%
IOVAIovance Biotherapeutics3.7-0.31-7.73%-- 
After Hours 3.7891 +0.0891 +2.41%
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using its novel cell penetrating peptide technology platform. Its flagship product candidate, nomlabofusp, is a subcutaneously administered recombinant fusion protein designed to deliver frataxin (FXN) to the mitochondria of patients with Friedreich's ataxia (FA), a rare genetic disease characterized by insufficient production of FXN. The company also plans to use its intracellular delivery platform to design other fusion proteins to target additional rare diseases characterized by deficiencies in intracellular bioactive compounds.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.